Front. Pediatr. Frontiers in Pediatrics Front. Pediatr. 2296-2360 Frontiers Media S.A. 10.3389/fped.2022.862484 Pediatrics Correction Corrigendum: Can We Optimize Antibiotic Use in Norwegian Neonates? A Prospective Comparison Between a University Hospital and a District Hospital Thaulow Christian Magnus 1 2 * Berild Dag 3 4 5 Blix Hege Salvesen 3 6 Brigtsen Anne Karin 7 Myklebust Tor Åge 8 Eriksen Beate Horsberg 9 1Clinical Institute II, University of Bergen, Bergen, Norway 2Department of Pediatrics, Haukeland University Hospital, Bergen, Norway 3Institute of Clinical Medicine, University of Oslo, Oslo, Norway 4Institute of Pharmacology, University of Oslo, Oslo, Norway 5Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway 6Department of Drug Statistics, Norwegian Institute of Public Health, Oslo, Norway 7Department of Pediatrics, Oslo University Hospital, Oslo, Norway 8Department of Research and Innovation, Møre and Romsdal Hospital Trust, Alesund, Norway 9Department of Pediatrics, Møre and Romsdal Hospital Trust, Oslo, Norway

Edited and reviewed by: Hans Van Rostenberghe, Universiti Sains Malaysia (USM), Malaysia

 *Correspondence: Christian Magnus Thaulow cmt85@hotmail.com

This article was submitted to Pediatric Infectious Diseases, a section of the journal Frontiers in Pediatrics

 10 03 2022 2022 10 862484 26 01 2022 08 02 2022 Copyright © 2022 Thaulow, Berild, Blix, Brigtsen, Myklebust and Eriksen. 2022 Thaulow, Berild, Blix, Brigtsen, Myklebust and Eriksen

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Corrigendum on Can We Optimize Antibiotic Use in Norwegian Neonates? A Prospective Comparison Between a University Hospital and a District Hospital by Thaulow, C. M., Berild, D., Blix, H. S., Brigtsen, A. K., Myklebust, T. Å., and Eriksen, B. H. (2019). Front. Pediatr. 7:440. doi: 10.3389/fped.2019.00440 neonatal antibiotic use antimicrobial resistance pediatric antibiotic stewardship antibiotic doses antibiotic prescriptions

In the original article, in Figure 2, the lines related to each mean value showed ±2 standard deviations from the 95% confidence intervals. The corrected Figure 2 appears below.

Mean maximum CRP level (n = 120) in relation to number of treatment days (GA ≥ 28 weeks) among Norwegian hospitalized neonates.

In the original article, there was a mistake in Table 3, 95% confidence intervals presented on the first line in the section describing treatments for unconfirmed EOS in premature infants were not correct, 91–103 should have been 90–100, 77–107 should have been 76–100 and 100 should have been 81–100. Moreover, 95% confidence intervals presented in the fifth line are not correct; 0–14 should be 0–22 for all, 0–14 should be 0–26 for the University Hospital and 0–14 should be 0–29 for the District Hospital. The corrected Table 3 appears below.

Characteristic in treatment of early-onset sepsis (EOS) in two Norwegian neonatal units, gestational age (GA) ≥ 28 weeks.

All University Hospital District Hospital P-valuea
All
EOS treatments, n 121 48 73
Confirmed EOSb, n (%, 95% CI) 21 (17, 10–24) 11 (23, 11–35) 10 (14, 6–22)
Unconfirmed EOS, n (%, 95% CI) 99 (82, 75–89) 36 (75, 63–87) 63 (86, 78–94)
Unknown (%) 1 (0.8) 1 (2) 0 (0) 0.172
Term infants (GA ≥37 weeks)
EOS treatments, n (%) 91 (75) 36 (75) 55 (75) 0.966
Confirmed EOS
Treatments, n (%, 95% CI) 21 (23, 14–32) 11 (31, 16–46) 10 (18, 8–28) 0.173
Treatment duration, mean (95% CI) 5.95 (5.4–6.5) 6.1 (5.3–6.9) 5.8 (5.3–6.3) 0.586
Maximum CRP, mean (95% CI) 61.1 (52.4–69.8) 61.0 (48.4–73.6) 61.3 (49.5–73.1) 0.975
Bloodcultures obtained, n (%) 21 (100) 11 (100) 10 (100) n/a
Positive bloodcultures, n (%, 95% CI) 2c (10, 0–22) 1 (10, 0–26) 1 (10, 0–29) 0.945
Respiratory support, n (%) 5 (24) 4 (36) 1 (10) 0.169
Unconfirmed EOS
Treatments, n (% 95% CI) 70 (77, 68–86) 25 (69, 54–84) 45 (82, 72–92) 0.173
Treatment duration, mean (95% CI) 3.01 (2.7–3.3) 3.2 (2.4–3.9) 3.0 (2.7–3.3) 0.709
Maximum CRP, mean (95% CI) 17.3 (12.9–21.5) 18.2 (12.0–24.5) 16.8 (11.6–22.9) 0.751
Bloodcultures obtained, n (%) 69 (99) 24 (96) 45 (100) 0.357
Respiratory support, n (%) 28 (40) 11 (44) 17 (38) 0.613
Premature infants (28–36 weeks)
EOS treatments, n (%) 30 (25) 12 (25) 18 (25) 0.966
Confirmed EOS
Treatments, n (%) 0 (0) 0 (0) 0 (0) n/a
Unconfirmed EOS
Treatments, n (%, 95% CI) 29 (97, 90–100) 11 (92, 76–100) 18 (100, 81–100) 0.221
Treatment duration, mean (95% CI) 3.03 (2.6–3.5) 3.4 (2.5–4.2) 2.8 (2.4–3.3) 0.313
Maximum CRP, mean (95% CI) 8.6 (4.1–13.1) 5.9 (−0.65–12.45) 10.2 (3.42–17.02) 0.305
Bloodculture obtained, n (%) 28 (97) 11 (100) 17 (94) 0.434
Respiratory support, n (%) 20 (69) 8 (73) 12 (67) 0.737
Unknown
Treatments, n (%) 1 (3.3) 1 (8.3) 0 (0) 0.222

Chi square test was used for proportions and Student's t-test for means. For “all treatments,” p-value was based on chi square test for all variables in the section.

Positive blood culture or CRP > 30 and minimum five days of treatment (or death before 5 days). Bloodcultures with Coagulase-negative staphylococci (CoNS) were considered positive if CRP > 10 and minimum 5 days of treatment (or death before 5 days).

One case of Streptococcus agalacticae (GBS) at the University hospital and one case of Staplylococcus epidermidis at the District hospital.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.